At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Open-Label Study of GSK1795091 Administered in Combination With Immunotherapies in Participants With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating GSK1795091, GSK3174998, and 2 other interventions for Neoplasms. Completed, enrolled 54 participants across 8 sites in 4 countries.
Detailed Summary
GSK1795091 is being developed for administration in combination with other immune system modulators for the treatment of cancers. The study will be conducted in two parts. In Part 1, dose escalation will be performed to identify combination dose levels comprising GSK1795091 with either 24 milligrams (mg) GSK3174998 (Part 1a), 80 mg GSK3359609 (Part 1b), or 200 mg pembrolizumab (Part 1c). One dose level of GSK3174998, GSK3359609, or pembrolizumab with up to 5 dose levels of GSK1795091 are planned for evaluation. In Part 2 (dose-expansion), subjects will receive a single dose level of GSK1795091 as identified based on data from Part 1, in combination with either GSK3174998, GSK3359609, or pembrolizumab.
Study Details
Timeline
Interventions
GSK1795091 will be available as solution for injection
GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.
GSK3359609 will be available as solution for infusion.
Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.